Literature DB >> 10484765

Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model.

J D Amack1, A P Paguio, M S Mahadevan.   

Abstract

The mutation causing myotonic dystrophy (DM) has been identified as a CTG expansion in the 3'-untranslated region (3'-UTR) of the DM protein kinase gene ( DMPK ), but the mechanism(s) of pathogenesis remain unknown. Studies using DM patient materials have often produced confusing results. Therefore, to study the effects of the DM mutation in a controlled environment, we have established a cell culture model system using C2C12 mouse myoblasts. By expressing chimeric reporter constructs containing a reporter gene fused to a human DMPK 3'-UTR, we identified both cis and trans effects that are mediated by the DM mutation. Our data show that a mutant DMPK 3'-UTR, with as few as 57 CTGs, had a negative cis effect on protein expression and resulted in the aggregation of reporter transcripts into discrete nuclear foci. We determined by deletion analysis that an expanded (CTG) (n) tract alone was sufficient to mediate these cis effects. Furthermore, in contrast to the normal DMPK 3'-UTR mRNA, a mutant DMPK 3'-UTR mRNA with (CUG)(200)selectively inhibited myogenic differentiation of C2C12 myoblasts. Genetic analysis and the Cre- loxP system were used to clearly demonstrate that the myoblast fusion defect could be rescued by eliminating the expression of the mutant DMPK 3'-UTR transcript. Characterization of spontaneous deletion events mapped the inhibitory effect to the (CTG) (n) expansion and/or the 3' end of the DMPK 3'-UTR. These results provide evidence that the DM mutation acts in cis to reduce protein production (consistent with DMPK haploinsufficiency) and in trans as a 'riboregulator' to inhibit myogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484765     DOI: 10.1093/hmg/8.11.1975

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  42 in total

Review 1.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 2.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

Review 3.  Noncoding RNA in development.

Authors:  Paulo P Amaral; John S Mattick
Journal:  Mamm Genome       Date:  2008-10-07       Impact factor: 2.957

4.  Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Qing Yu; Sadguna Balijepalli; Carla D Frenzel-McCardell; T David Bourne; Lawrence H Phillips
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

5.  A novel molecular mechanism in human genetic disease: a DNA repeat-derived lncRNA.

Authors:  Daphne S Cabianca; Valentina Casa; Davide Gabellini
Journal:  RNA Biol       Date:  2012-10-01       Impact factor: 4.652

Review 6.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 7.  Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.

Authors:  Laura P W Ranum; John W Day
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

Review 9.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.

Authors:  Morgan A Sammons; Amanda K Antons; Mourad Bendjennat; Bjarne Udd; Ralf Krahe; Andrew J Link
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.